Long-term aquaretic efficacy of a selective nonpeptide V2-vasopressin receptor antagonist, SR121463, in cirrhotic rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 295, Issue 1, 2000, Pages 83-90

  Jiménez, Wladimiro ^a   Serradeil Le Gal, Claudine ^b   Ros, Josefa ^a   Cano, Carmen ^a   Cejudo, Pilar ^a   Morales Ruiz, Manuel ^a   Arroyo, Vicente ^a   Pascal, Marc ^a,b   Rivera, Francisca ^c   Maffrand, Jean Pierre ^b   Rod́s, Juan ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b SANOFI   (France)

^c Hospital Clinic Universitari ^*

Author keywords

[No Author keywords available]

Indexed keywords

N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; NIRAVOLINE; VASOPRESSIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM MOBILIZATION; CONTROLLED STUDY; DIURESIS; DRUG EFFICACY; FLUID BALANCE; HYPONATREMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LIVER CIRRHOSIS; MEAN ARTERIAL PRESSURE; NONHUMAN; PLASMA OSMOLARITY; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SODIUM EXCRETION; VASOPRESSIN RELEASE; WATER RETENTION;

EID: 0033810608     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. 2 receptors
2. Species heterogeneity and antidiuretic hormone antagonists: What are the predictors?
3. Antidiuretic hormone and pathogenesis of water retention in cirrhosis with ascites
4. Systemic and regional hemodynamic and biological effects of a new κ-opioid agonist, niravoline, in healthy volunteers
5. Vasopressin receptors in health and disease
6. Comparison between two aquaretic drugs (niravoline vs OPC-31260) in cirrhotic rats with ascites and water retention
7. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
8. Determination of SR 49059 in human plasma and urine by LC-APCI/MS/MS
9. Temporal relationship between the impairment of free water excretion and antidiuretic hormone hypersecretion in rats with experimental cirrhosis
10. Renal dysfunction and ascites in carbon tetrachloride-induced cirrhosis in rats
11. Hyponatremia in cirrhosis: From pathogenesis to treatment
12. Dynamics effects of a novel, non-peptide ADH (V2) antagonist in cirrhotic patients with ascites
13. Kappa agonists and vasopressin secretion
14. Mechanisms of action of vasopressin and vasopressin antagonists
15. Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis
16. Vasopressin antagonists and their use in animal studies
17. No requirement of cyclic conformation of antagonists in binding to vasopressin receptors
18. Sodium and water retention in heart failure: Pathogenesis and treatment
19. Ligand: A versatile computerized approach for characterization of ligand-binding systems
20. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men
21. 2+ transport by rat liver plasma membranes vesicles
22. Pathophysiology of water metabolism: Water retaining disorders
23. Vasopressin analogues that antagonize antidiuretic responses by rats to the anti-diuretic hormone
24. A radioiodinated linear vasopressin antagonist: A ligand with high affinity and specific for V(1a) receptors
25. 2 receptor antagonist
26. Molecular mechanisms of novel antidiuretic antagonist: Analysis of the effects on vasopressin binding and adenylate cydase activation in animal and human kidney
27. Critical differences between species in the in vivo and in vitro renal responses to antidiuretic hormone antagonists
28. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats
29. 2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats
30. 2 receptor antagonist